Zhejiang Medicine Co Ltd

SHG:600216 China Drug Manufacturers - Specialty & Generic
Market Cap
$2.33 Billion
CN¥17.08 Billion CNY
Market Cap Rank
#6104 Global
#886 in China
Share Price
CN¥17.76
Change (1 day)
+2.66%
52-Week Range
CN¥12.08 - CN¥18.38
All Time High
CN¥20.16
Categories
Companies in China Drug Manufacturers - Specialty & Generic
About

Zhejiang Medicine Co., Ltd. manufactures and sells life nutrition and medical products in China and internationally. The company offers synthetic vitamin E, natural vitamin E, ß-carotene, cantharidin, vancomycin hydrochloride, and teicoplanin. It also provides fat-soluble vitamins, retinoids, quinolone antibiotics, anti-resistance antibiotics, and other products, as well as animal nutrition produ… Read more

Zhejiang Medicine Co Ltd (600216) - Net Assets

Latest net assets as of September 2025: CN¥11.21 Billion CNY

Based on the latest financial reports, Zhejiang Medicine Co Ltd (600216) has net assets worth CN¥11.21 Billion CNY as of September 2025.

Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥14.14 Billion) and total liabilities (CN¥2.92 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.

Key Net Assets Metrics

Metric Value
Current Net Assets CN¥11.21 Billion
% of Total Assets 79.31%
Annual Growth Rate 14.16%
5-Year Change 35.34%
10-Year Change 64.29%
Growth Volatility 25.93

Zhejiang Medicine Co Ltd - Net Assets Trend (1997–2024)

This chart illustrates how Zhejiang Medicine Co Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.

Annual Net Assets for Zhejiang Medicine Co Ltd (1997–2024)

The table below shows the annual net assets of Zhejiang Medicine Co Ltd from 1997 to 2024.

Year Net Assets Change
2024-12-31 CN¥10.87 Billion +8.83%
2023-12-31 CN¥9.99 Billion +2.85%
2022-12-31 CN¥9.71 Billion +5.75%
2021-12-31 CN¥9.18 Billion +14.35%
2020-12-31 CN¥8.03 Billion -2.69%
2019-12-31 CN¥8.25 Billion +2.08%
2018-12-31 CN¥8.08 Billion +3.92%
2017-12-31 CN¥7.78 Billion +11.26%
2016-12-31 CN¥6.99 Billion +5.69%
2015-12-31 CN¥6.62 Billion +0.81%
2014-12-31 CN¥6.56 Billion +1.25%
2013-12-31 CN¥6.48 Billion +4.57%
2012-12-31 CN¥6.20 Billion +40.83%
2011-12-31 CN¥4.40 Billion +13.90%
2010-12-31 CN¥3.86 Billion +35.02%
2009-12-31 CN¥2.86 Billion +57.89%
2008-12-31 CN¥1.81 Billion +107.42%
2007-12-31 CN¥873.73 Million +12.40%
2006-12-31 CN¥777.31 Million +6.16%
2005-12-31 CN¥732.23 Million +13.40%
2004-12-31 CN¥645.68 Million +2.74%
2003-12-31 CN¥628.48 Million -0.20%
2002-12-31 CN¥629.71 Million +3.49%
2001-12-31 CN¥608.50 Million -4.18%
2000-12-31 CN¥635.03 Million +1.59%
1999-12-31 CN¥625.07 Million +79.30%
1998-12-31 CN¥348.61 Million +14.61%
1997-12-31 CN¥304.17 Million --

Equity Component Analysis

This analysis shows how different components contribute to Zhejiang Medicine Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have grown by 21269.2% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2024)

Component Amount Percentage
Retained Earnings CN¥5.93 Billion 55.72%
Common Stock CN¥961.64 Million 9.03%
Other Comprehensive Income CN¥2.70 Billion 25.32%
Other Components CN¥1.06 Billion 9.93%
Total Equity CN¥10.65 Billion 100.00%

Zhejiang Medicine Co Ltd Competitors by Market Cap

The table below lists competitors of Zhejiang Medicine Co Ltd ranked by their market capitalization.

Company Market Cap
SPAREBK 1 NORD-NORGE NK18
F:93S
 		$1.38 Billion
BRAZE INC. A DL-0001
F:K43
 		$1.38 Billion
Kiler Holding A.S.
IS:KLRHO
 		$1.38 Billion
Kontron AG
VI:KTN
 		$1.39 Billion
Polaris Bay Group Co Ltd
SHG:600155
 		$1.38 Billion
Foreign Trade Bank of Latin America Inc
NYSE:BLX
 		$1.38 Billion
Vcanbio Cell & Gene Engineering Corp Ltd
SHG:600645
 		$1.38 Billion
Diagnostyka S.A.
WAR:DIA
 		$1.38 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Zhejiang Medicine Co Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2023 to 2024, total equity changed from 9,630,715,541 to 10,648,142,085, a change of 1,017,426,544 (10.6%).
  • Net income of 1,160,510,673 contributed positively to equity growth.
  • Dividend payments of 142,577,037 reduced retained earnings.
  • Share repurchases of 29,001,735 reduced equity.
  • Other comprehensive income increased equity by 2,690,319,823.
  • Other factors decreased equity by 2,661,825,180.

Equity Change Factors (2023 to 2024)

Factor Impact Contribution
Net Income CN¥1.16 Billion +10.9%
Dividends Paid CN¥142.58 Million -1.34%
Share Repurchases CN¥29.00 Million -0.27%
Other Comprehensive Income CN¥2.69 Billion +25.27%
Other Changes CN¥-2.66 Billion -25.0%
Total Change CN¥- 10.56%

Book Value vs Market Value Analysis

This analysis compares Zhejiang Medicine Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 1.60x
  • The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
  • The price-to-book ratio has decreased from 47.13x to 1.60x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
1997-12-31 CN¥0.38 CN¥17.76 x
1998-12-31 CN¥0.43 CN¥17.76 x
1999-12-31 CN¥0.77 CN¥17.76 x
2000-12-31 CN¥0.79 CN¥17.76 x
2001-12-31 CN¥0.75 CN¥17.76 x
2002-12-31 CN¥0.77 CN¥17.76 x
2003-12-31 CN¥0.78 CN¥17.76 x
2004-12-31 CN¥0.80 CN¥17.76 x
2005-12-31 CN¥0.90 CN¥17.76 x
2006-12-31 CN¥0.95 CN¥17.76 x
2007-12-31 CN¥1.11 CN¥17.76 x
2008-12-31 CN¥2.22 CN¥17.76 x
2009-12-31 CN¥3.52 CN¥17.76 x
2010-12-31 CN¥4.75 CN¥17.76 x
2011-12-31 CN¥5.42 CN¥17.76 x
2012-12-31 CN¥7.29 CN¥17.76 x
2013-12-31 CN¥6.86 CN¥17.76 x
2014-12-31 CN¥6.93 CN¥17.76 x
2015-12-31 CN¥6.93 CN¥17.76 x
2016-12-31 CN¥7.44 CN¥17.76 x
2017-12-31 CN¥7.77 CN¥17.76 x
2018-12-31 CN¥7.97 CN¥17.76 x
2019-12-31 CN¥8.20 CN¥17.76 x
2020-12-31 CN¥8.01 CN¥17.76 x
2021-12-31 CN¥9.16 CN¥17.76 x
2022-12-31 CN¥9.66 CN¥17.76 x
2023-12-31 CN¥10.09 CN¥17.76 x
2024-12-31 CN¥11.10 CN¥17.76 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Zhejiang Medicine Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 10.90%
  • The company shows good efficiency in utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 12.38%
  • • Asset Turnover: 0.68x
  • • Equity Multiplier: 1.30x
  • Recent ROE (10.90%) is above the historical average (10.71%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
1997 12.22% 4.05% 0.97x 3.12x CN¥6.73 Million
1998 10.45% 3.27% 0.97x 3.30x CN¥1.53 Million
1999 5.36% 2.80% 0.69x 2.78x CN¥-28.75 Million
2000 1.29% 0.76% 0.75x 2.27x CN¥-55.19 Million
2001 2.73% 1.89% 0.55x 2.61x CN¥-43.61 Million
2002 3.03% 1.68% 0.68x 2.64x CN¥-43.17 Million
2003 0.92% 0.51% 0.68x 2.67x CN¥-56.69 Million
2004 1.99% 0.92% 0.75x 2.87x CN¥-51.29 Million
2005 11.27% 4.33% 0.85x 3.05x CN¥9.18 Million
2006 7.59% 2.66% 0.87x 3.28x CN¥-18.60 Million
2007 6.51% 2.56% 0.78x 3.27x CN¥-30.30 Million
2008 54.05% 25.86% 1.15x 1.81x CN¥792.68 Million
2009 42.60% 29.01% 1.08x 1.36x CN¥928.84 Million
2010 29.68% 25.11% 0.98x 1.20x CN¥758.99 Million
2011 23.06% 20.98% 0.93x 1.18x CN¥573.39 Million
2012 13.72% 16.12% 0.75x 1.14x CN¥229.90 Million
2013 7.00% 9.16% 0.65x 1.17x CN¥-193.72 Million
2014 2.60% 3.51% 0.61x 1.20x CN¥-484.09 Million
2015 2.45% 3.60% 0.55x 1.25x CN¥-497.73 Million
2016 6.45% 8.53% 0.60x 1.26x CN¥-247.72 Million
2017 3.47% 4.45% 0.58x 1.34x CN¥-475.78 Million
2018 4.77% 5.32% 0.68x 1.31x CN¥-400.13 Million
2019 4.36% 4.87% 0.68x 1.32x CN¥-443.31 Million
2020 9.35% 9.79% 0.70x 1.37x CN¥-50.06 Million
2021 11.91% 11.45% 0.73x 1.43x CN¥167.41 Million
2022 5.83% 6.65% 0.65x 1.34x CN¥-386.42 Million
2023 4.46% 5.51% 0.61x 1.33x CN¥-533.43 Million
2024 10.90% 12.38% 0.68x 1.30x CN¥95.70 Million

Industry Comparison

This section compares Zhejiang Medicine Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

  • Industry: Drug Manufacturers - Specialty & Generic
  • Average net assets among peers: $2,123,990,643
  • Average return on equity (ROE) among peers: -0.22%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Zhejiang Medicine Co Ltd (600216) CN¥11.21 Billion 12.22% 0.26x $1.38 Billion
Shenzhen Neptunus Bioengineering Co Ltd (000078) $6.47 Billion 9.88% 3.77x $616.08 Million
Anhui Fengyuan Pharmaceutical Co Ltd (000153) $1.18 Billion 2.74% 0.95x $320.56 Million
Shan Dong Dong-E E-Jiao Co Ltd (000423) $10.33 Billion 15.07% 0.27x $3.03 Billion
Wedge Industrial Co Ltd (000534) $298.72 Million 1.96% 0.38x $1.77 Billion
Yunnan Baiyao Group Co Ltd (000538) $35.11 Million 18.13% 0.80x $5.62 Billion
Hainan Haiyao Co Ltd (000566) $353.98 Million -9.58% 0.80x $702.18 Million
Tus Pharmaceutical Group Co Ltd (000590) $269.51 Million -61.02% 1.05x $317.08 Million
Northeast Pharmaceutical Group Co Ltd (000597) $927.49 Million 2.65% 1.38x $425.60 Million
Jilin Aodong Pharmaceutical Group Co Ltd (000623) $1.11 Billion 7.32% 0.29x $2.05 Billion
Renhe Pharmacy Co Ltd (000650) $261.49 Million 10.60% 0.82x $777.45 Million